Arm 1- Dose Escalation

DRUG2 trials

Sponsors

Amgen

Conditions

Advanced MalignancyAdvanced Solid TumorsCancerHematologic MalignanciesLeukemiaMyeloid LeukemiaSolid TumorsTumors

Phase 1

A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors

CompletedNCT00858377

AmgenAdvanced Malignancy, Advanced Solid Tumors, Cancer +2

Start: 2009-08-10End: 2019-04-03Updated: 2019-05-06

Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

CompletedNCT01380756

AmgenCancer, Hematologic Malignancies, Leukemia +1

Start: 2011-10-04End: 2014-09-04Updated: 2017-11-06

Related Papers

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

2018-07-0733 citations

Abstract 439: Detection of aurora kinase A (AURKA) focal amplification in plasma samples of patients with recurrent ovarian cancer

Cancer Research2016-07-151 citations

Abstract CT045: Phase 1, open-label, first-in-human study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors

Cancer Research2016-07-151 citations

Population pharmacokinetics (pop PK) and exposure-safety analysis to reveal patient factors that affect AMG 900 tolerability.

Journal of Clinical Oncology2016-05-20

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Blood2015-12-032 citations